Kerala SMA children get generic drug labelled 'clinical trial' at SAT Hospital
Parents of children with spinal muscular atrophy in Kerala are asking whether the cheaper generic they were switched to this week is approved, tested and properly explained to them.

Parents of children with spinal muscular atrophy (SMA) in Kerala got a shock this week. The medicine handed out at Thiruvananthapuram's SAT Hospital had been switched to a cheaper generic, and its packaging carried the words "Physician Sample" and "For Clinical Trials Only".
Until now, these children had been getting Evrysdi, the original risdiplam drug made by Roche. The new bottles hold Natsmart, a made-in-India generic from Hyderabad-based Natco Pharma. Many parents feared their kids were suddenly being given an experimental medicine.
The questions go beyond the label. People want to know what regulatory approval the generic has for this use, what proof shows it works as well as the original (the technical term is bioequivalence), and whether families were told clearly about the change and asked for their consent. Opposition leader and former chief minister Pinarayi Vijayan raised the matter on October 20.
The stakes are high because SMA is a rare genetic condition that steadily weakens muscles and can be fatal in severe forms. Risdiplam helps the body make more of a protein it lacks. It is not a cure, but it can slow the disease, and it works best when started early.
Kerala has been the only Indian state giving eligible children free SMA treatment since 2022. The scheme later became part of the Kerala United Against Rare Diseases (KARE) programme, which covers children under 12. Around 200 patients are believed to benefit. The price the state paid Roche has not been made public.
The original drug is hugely expensive. It could cost about Rs 72 lakh a year in the first two years of treatment and Rs 56 lakh a year after that. Last year the Delhi High Court allowed Natco to make a generic version, which it launched at Rs 15,900 a bottle. That is nearly 97% below the Rs 6.2 lakh the imported version could cost per bottle.
So the logic of the switch is easy to see: far cheaper treatment could keep a free programme running for longer. But for families whose children depend on this medicine every day, savings are not enough. They want clear answers on approval, evidence and consent before they feel comfortable with the change.
Read the original report: Kerala's free SMA scheme faces questions over generic drug's 'clinical trial' label.